COVID-19 Vaccine Associated Myopericarditis

See also: CoVid-19 Vaccine Associated Myocarditis and CoVid-19 Vaccine Associated Pericarditis

Myopericarditis following COVID-19 vaccination: Updates from the Vaccine. Adverse Event Reporting System (VAERS). CDC Aug 30, 2021.

 2,574 reports of myopericarditis or pericarditis to VAERS (as of August 18, 2021)

• 1,903 myopericarditis, 671 pericarditis

 Epidemiology of myopericarditis following COVID-19 vaccination similar to previously reported updates

• Primarily in younger males, after dose 2 mRNA vaccination, symptom onset clustering within several days of vaccination

 Limited follow-up information in VAERS case reports suggests most patients (77%) recovered from symptoms at time of report or follow-up

 Observed vs. Expected analysis with VAERS reports

• Males: Observed > Expected in age groups through 49 years • Females: Observed > Expected in age groups through 29 years

 Enhanced surveillance for myocarditis outcomes after mRNA COVID-19 vaccination in VAERS case reports is ongoing

Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents

Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age

Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents

Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19

Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis

COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis.

Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model

Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report

Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male

Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents

Acute myopericarditis after COVID-19 vaccine in adolescents

Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389 .

Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083

mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. [[https://www.ncbi.nlm.nih.gov/pubmed/34332972|Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds.2021.07.057

Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322

Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016/j.cjco.2021.12.002

Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019

Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report